Results of a phase II study with sunitinilb malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)

被引：0
|
作者：
Kulka, M.
Lenz, H.
Meropol, N.
Posey, J.
Picus, J.
Ryan, D.
Bergsland, E.
Stuart, K.
Baum, C.
Fuchs, C.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Calif Los Angeles, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Univ Alabama, Birmingham, AL USA
[5] Washington Univ, St Louis, France
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[8] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[9] Pfizer Inc, La Jolla, CA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [41] Phase III randomized trial of sunitinib malate (SU11248) versus interferon- alfa (IFN-A) as first-line systemic therapy for patients with metastatic renal cell carcinoma (MRCC)
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    ANNALS OF ONCOLOGY, 2006, 17 : 53 - 54
  • [42] Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)
    Abdelraouf, Fatma
    Smit, Egbert
    Hasan, Baktiar
    Menis, Jessica
    Popat, Sanjay
    van Meerbeeck, Jan P.
    Surmont, Veerle F.
    Baas, Paul
    O'Brien, Mary
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 35 - 39
  • [43] A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy.
    Foran, J
    Paquette, R
    Cooper, M
    Jacobs, M
    O'Farrell, AM
    Kim, H
    Cherrington, J
    Scigalla, P
    BLOOD, 2002, 100 (11) : 558A - 559A
  • [44] Continuous daily dosing (CDD) study of sunitinib malate (SU) in patients (pts) with advanced GIST compares favorably with intermittent dosing
    Blay, J. Y.
    George, S.
    Casali, P. G.
    Le Cesne, A.
    Morgan, J. A.
    Pokela, J.
    Quigley, M. T.
    Tasse, V.
    Baum, C. M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 402 - 402
  • [45] Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumours (NETs)
    Hernando Cubero, J.
    Grande, E.
    Castellano Gauna, D.
    Ibrahim, T.
    Fazio, N.
    Lopez, C.
    Teule, A.
    Valle, J. W.
    Alonso, V.
    Molina-Cerrillo, J.
    Tafuto, S.
    Custodio, A.
    Trejo, L.
    Casteras, A.
    Manneh Kopp, R.
    Miqueo, C.
    Roca Herrera, M.
    Garcia-Carbonero, R.
    Salazar, R.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 567 - 567
  • [46] A phase II study of interferon alpha-2a (IFN alpha) and modulated 5-fluorouracil (5-FU) in patients (pts) with advanced neuroendocrine tumours (NET)
    Papamichael, D
    Penson, RT
    Seymour, MT
    Wilson, P
    Gallagher, CJ
    Besser, GM
    Slevin, ML
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1235 - 1235
  • [47] Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Strosberg, J.
    Campos, T.
    Kvols, L.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 136 - 136
  • [48] Phase I study of ATN-224 in patients (pts) with advanced solid tumours.
    Lowndes, S. A.
    Adams, A.
    Timms, A.
    Middleton, M.
    Hayward, C.
    Reich, S. D.
    Mazar, A. P.
    Harris, A. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 95S - 95S
  • [49] Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice
    Carmona-Bayonas, A.
    Jimenez-Munarriz, B.
    Jimenez-Fonseca, P.
    Custodio, A.
    Alonso, V
    Alonso, T.
    Lopez, C.
    Matos, I
    Crespo, G.
    Garcia-Paredes, B.
    Aller, J.
    Grande, E.
    Capdevila, J.
    Sastre, J.
    Barriuso, J.
    NEUROENDOCRINOLOGY, 2016, 103 : 79 - 80
  • [50] PAZONET: Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)-NCT01280201
    Grande Pulido, Enrique
    Castellano, Daniel E.
    Garcia-Carbonero, Rocio
    Teule, Alex
    Duran, Ignacio
    Fuster, Jose
    Sevilla, Isabel
    Escudero, P.
    Sastre, Javier
    Capdevila, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345